Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy

BACKGROUND: Recently, anti-CD38 monoclonal antibody (Mab) therapy has become a focus of attention as an additional/alternative option for many hematological neoplasms including T-cell acute lymphoblastic leukemia (T-ALL). It has been shown that antitumor efficacy of anti-CD38-Mab depends on the leve...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: Tembhare, Prashant Ramesh, Sriram, Harshini, Khanka, Twinkle, Chatterjee, Gaurav, Panda, Devasis, Ghogale, Sitaram, Badrinath, Yajamanam, Deshpande, Nilesh, Patkar, Nikhil V, Narula, Gaurav, Bagal, Bhausaheb, Jain, Hasmukh, Sengar, Manju, Khattry, Navin, Banavali, Shripad, Gujral, Sumeet, Subramanian, Papagudi G
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2020
Soggetti:
Basic Tumor Immunology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7247386/
https://ncbi.nlm.nih.gov/pubmed/32439800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000630
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi